Search results for " Antibodies"

showing 10 items of 383 documents

Fixation conditions affect the intensity but not the pattern of NADPH-diaphorase staining as a marker for neuronal nitric oxide synthase in rat olfac…

1994

NADPH-diaphorase (NADPH-d) is commonly used as a histochemical marker for the neuronal form of the enzyme nitric oxide synthase (NOS). A recent biochemical study showed that in broken-cell preparations NADPH-d activity did not fully represent NOS and that NOS-unrelated NADPH-d activity was suppressed during fixation. Because it is unknown whether fixation also affects NOS-associated NADPH-d activity, we investigated the effects of various widely used fixatives on NADPH-d staining in relation to NOS immunoreactivity, obtained with polyclonal antibodies, in rat olfactory bulb. We found that the intensity of NADPH-d staining associated with NOS, as well as that unrelated to NOS, depends on fi…

MalePathologymedicine.medical_specialtyTissue FixationHistologyLysineSensitivity and SpecificityStainImmunoenzyme TechniquesRats Sprague-DawleymedicineAnimalsFixativeNeuronschemistry.chemical_classificationStaining and LabelingbiologyChemistryNADPH DehydrogenaseOlfactory BulbMolecular biologyRatsOlfactory bulbStainingNitric oxide synthaseEnzymePolyclonal antibodiesbiology.proteinAmino Acid OxidoreductasesNitric Oxide SynthaseAnatomyBiomarkersJournal of Histochemistry & Cytochemistry
researchProduct

Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

2016

The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×109 L−1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corti…

MalePediatricsAdministration OralDiseaseChurg-Strauss SyndromeBronchoalveolar LavageSeverity of Illness Index0302 clinical medicineAdrenal Cortex HormonesEosinophilicEosinophiliaAged 80 and overNomenclatureSystemic VasculitisCohortMiddle AgedTerm-follow-upPrognosis3. Good healthRespiratory Function TestsManagementTreatment OutcomeCohortAntineutrophil cytoplasmic antibodiesPopulation studyFemaleFrancemedicine.symptomGranulomatosis with polyangiitisConsensus conferencePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAdolescentVasculitides[ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology environment/HealthGranulomatosis03 medical and health sciencesYoung AdultEosinophiliamedicineHumansAnti-neutrophil cytoplasmic antibodyAsthmaAgedRetrospective Studies030203 arthritis & rheumatology[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Healthbusiness.industryGranulomatosis with Polyangiitisasthmamedicine.diseaseEosinophils030228 respiratory systemImmunologybusinessTomography X-Ray Computed
researchProduct

Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period

2007

BACKGROUND & AIMS: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. METHODS: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. RESULTS: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon alpha. Ten years after putative exposure, the out…

MalePediatricsEpidemiologyInfectious Disease TransmissionCHILDRENHepacivirusmedicine.disease_causeGENOTYPES HCVRisk FactorsEpidemiologyPrevalenceVerticalChronicYoung adultChildHCV infection in childrenbiologyHepatitis C virus (HCV)Hepatitis CANTI-HCVHepatitis CItalyChild PreschoolHCVFemaleViral diseaseAdultmedicine.medical_specialtyEpidemiology of HCV infectionGenotypepediatricsHepatitis C virusSocio-culturaleEnzyme-Linked Immunosorbent AssayFlaviviridaeHCV vertical transmissionmedicineHumansBlood TransfusionSex DistributionPreschoolRetrospective StudiesEpidemiology of HCV infection; HCV infection in children; HCV vertical transmission; Hepatitis C virus (HCV); Adult; Blood Transfusion; Child; Child Preschool; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Infant; Infectious Disease Transmission Vertical; Italy; Male; Prevalence; Retrospective Studies; Risk Factors; Sex Distribution; HepatologyHepatologybusiness.industryHIVInfantRetrospective cohort studyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseasebiology.organism_classificationHEPATITIS HCVInfectious Disease Transmission VerticalEl NiñoImmunologybusiness
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Management of Graves‘Thyroidal And Extrathyroidal Disease – An Update

2020

Abstract Context Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO). Evidence acquisition Guidelines, pertinent original articles, systemic reviews, and meta-analyses. Evidence synthesis Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistent…

MalePediatricsendocrine system diseasesdiagnosisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGraves' diseaseClinical Biochemistryradioactive iodineThyroid GlandBiochemistryHyperthyroidismIodine Radioisotopes0302 clinical medicineEndocrinologyPregnancyUltrasonographytreatmentDisease ManagementReceptors ThyrotropinMini-ReviewGraves Disease030220 oncology & carcinogenesisthyroidectomyBiomarker (medicine)antithyroid drugsFemaleAcademicSubjects/MED00250managementmedicine.drugImmunoglobulins Thyroid-Stimulatingmedicine.medical_specialtyendocrine system030209 endocrinology & metabolismContext (language use)TSH receptor antibodiesDiagnosis Differential03 medical and health sciencesAntithyroid AgentsInternal medicinemedicineHumansRisk factorPregnancyMethimazolebusiness.industryBiochemistry (medical)Thyroidectomymedicine.diseaseGraves OphthalmopathyPregnancy ComplicationsEndocrinologyPropylthiouracilDifferential diagnosisbusinessGraves’ diseaseBiomarkersThe Journal of Clinical Endocrinology and Metabolism
researchProduct

Use of monoclonal and polyclonal antibodies as structural and topographical probes for hepatic epoxide hydrolase

1983

AbstractMonoclonal antibodies have been prepared against rat liver epoxide hydrolase (EH), some of which gave precipitation lines on immunodiffusion against pure EH suggesting the presence of repetitive structural domains on the enzyme. Using ELISA, with polyclonal antibodies to rat and rabbit liver EH, reactivity and therefore structural similarities between EH of all species tested, including human, were observed. This was in contrast to immunodiffusion results demonstrating the limitations of the latter technique. Using monoclonal antibodies in ELISA, greatest structural similarity was between rat, mouse, and Syrian hamster EH and relatively little between rat and human. Two of the antib…

MalePrimatesMonoclonal antibodyImmunodiffusionmedicine.drug_classGuinea PigsBiophysicsHamsterEpoxide hydrolaseMonoclonal antibodyBiochemistryAntibodiesMiceEnzyme-linked immunosorbent assayStructural BiologyCricetinaeGeneticsmedicineAnimalsHumansEpoxide hydrolaseMolecular BiologyEpoxide HydrolasesbiologyChemistryEndoplasmic reticulumAntibodies MonoclonalRats Inbred StrainsCell BiologyMolecular biologyRatsImmunodiffusionLiverBiochemistryPolyclonal antibodiesMembrane topologyMonoclonalProtein structurebiology.proteinEpoxy CompoundsRabbitsAntibodyFEBS Letters
researchProduct

A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area

2020

Background Data on the true prevalence of hepatitis C virus (HCV) infection in the general population is essential. We evaluated a program implementing free universal HCV screening using a non-invasive point-of-care test (POCT) (OraQuick-HCV rapid test) in oral fluid in an urban area in Valencia, South-Eastern Spain. Methods A cross-sectional study was performed during 2015–2017. Free HCV screening was offered by regular mail to 11,500 individuals aged 18 and over, randomly selected from all census residents in the Health Department. All responding participants filled in a questionnaire about HCV infection risk factors and were tested in their tertiary Hospital. In those with a positive POC…

MaleRNA virusesSustained Virologic ResponseUrban PopulationEpidemiologyPhysiologyCross-sectional studyHepacivirusmedicine.disease_causeBiochemistryGeographical locations0302 clinical medicineRisk FactorsImmune PhysiologyPrevalence030212 general & internal medicineEnzyme-Linked ImmunoassaysYoung adultPathology and laboratory medicineAged 80 and overResponse rate (survey)education.field_of_studyImmune System ProteinsMultidisciplinaryHepatitis C virusQRMiddle AgedMedical microbiologyHepatitis CEuropeVirusesRNA ViralMedicineFemale030211 gastroenterology & hepatologyStandardized ratePathogensResearch ArticleAdultmedicine.medical_specialtyAdolescentPoint-of-Care SystemsScienceHepatitis C virusPoint-of-care testingImmunologyPopulationResearch and Analysis MethodsAntiviral AgentsMicrobiologyAntibodiesYoung Adult03 medical and health sciencesInternal medicinemedicineHumansEuropean UnionRisk factorImmunoassayseducationAgedMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryOrganismsViral pathogensProteinsHepatitis C AntibodiesFibrosisHepatitis virusesMicrobial pathogensHealth CareCross-Sectional StudiesSpainMedical Risk FactorsImmunologic TechniquesInterferonsPeople and placesbusinessDevelopmental BiologyPLOS ONE
researchProduct

Demonstration of antibodies to the surface (anti-p41) and core proteins (anti-p24) of the human immunodeficiency virus (HIV) in individuals positive …

1987

Diagnosis of infection with the human immunodeficiency virus (HIV) relies on the demonstration of antibody to this virus. Occasionally, the combined analysis of sera using ELISA and western blot reveals false-positive results. We have compared a newly developed test to detect antibodies to the core (anti-p24) and surface (anti-p41) proteins of HIV with the established tests described above. Anti-p24 and anti-p41 were negative in three individuals positive for anti-HIV by ELISA and immunoblot; they had a low risk to acquire HIV infection and were clinically and immunologically normal and suspected false positive previously. In 62 individuals at risk, anti-p41 was always positive while anti-p…

MaleRiskRetroviridae Proteins OncogenicHuman immunodeficiency virus (HIV)Retroviridae ProteinsEnzyme-Linked Immunosorbent AssayHIV Antibodiesmedicine.disease_causeAntibodies ViralVirusAcquired immunodeficiency syndrome (AIDS)Western blotViral Envelope ProteinsAntibody SpecificityDrug DiscoverymedicineHumansGenetics (clinical)Acquired Immunodeficiency Syndromebiologymedicine.diagnostic_testAnti hivvirus diseasesHIVCore proteinGeneral Medicinemedicine.diseaseVirologyHIV Envelope Protein gp41Immunologybiology.proteinMolecular MedicineFemaleAntibodyKlinische Wochenschrift
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

A comparative study on cell wall antigens and cell surface hydrophobicity in clinical isolates ofCandida albicans

1994

Characterization of common cell surface-bound antigens in Candida albicans strains, particularly those expressed in the walls of mycelial cells might be useful in the diagnosis of systemic candidiasis. Hence, antigenic similarities among wall proteins and mannoproteins from C. albicans clinical serotype A and B isolates, were studied using polyclonal (mPAbs) and monoclonal (MAb 4C12) antibodies raised against wall antigens from the mycelial form of a common C. albicans serotype A laboratory strain (ATCC 26555). Zymolyase digestion of walls isolated from cells of the different strains studied grown at 37 degrees C (germination conditions), released, in all cases, numerous protein and mannopr…

MaleSerotypeAntigens FungalVeterinary (miscellaneous)Blotting WesternPopulationApplied Microbiology and BiotechnologyMicrobiologyAntibodiesMicrobiologyCell wallAntigenCell WallCandida albicansmedicineAnimalsHumansCandida albicanseducationeducation.field_of_studybiologyCandidiasisbiology.organism_classificationmedicine.diseaseCorpus albicansPolyclonal antibodiesAntigens Surfacebiology.proteinElectrophoresis Polyacrylamide GelFemaleRabbitsSystemic candidiasisAgronomy and Crop ScienceMycopathologia
researchProduct